GlassScriptPhysician profile
Joel M Lamon
NPI 1699721035
$8,297.17
in general payments reported to CMS, 2019-2025
60 companies · $2,635 in 2025
The $2,635 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $204 · 2021: $757 · 2022: $971 · 2023: $1,112 · 2024: $2,289 · 2025: $2,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,937 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,936.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $974.27 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $886.56 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $411.91 | 2021-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $353.52 | 2022-2024 | Libtayo |
| Array Biopharma INC | $349.42 | 2022-2025 | Mektovi, Braftovi, Xalkori |
| E.R. Squibb & Sons, L.L.C. | $348.99 | 2019-2025 | Reblozyl, Opdivo |
| Genzyme Corporation | $336.20 | 2024-2025 | |
| Abbvie INC. | $293.56 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $274.91 | 2021-2025 | Xpovio |
| Eisai INC. | $264.66 | 2021-2025 | |
| Planmeca USA, INC. | $260.43 | 2021 | |
| Genentech USA, INC. | $233.95 | 2019-2025 | Polivy, Itovebi, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $205.06 | 2024-2025 | Imfinzi |
| Exelixis INC. | $184.08 | 2020-2025 | Cabometyx |
| Gilead Sciences, INC. | $162.21 | 2021-2025 | Trodelvy |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $161.41 | 2020-2023 | Tivdak, Padcev |
| Beigene USA, INC. | $158.10 | 2024-2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $156.71 | 2021-2025 | Ayvakit |
| Celgene Corporation | $151.30 | 2021-2025 | Reblozyl, Pomalyst |
| Beone Medicines USA, INC. | $143.88 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $130.60 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $124.78 | 2024-2025 | |
| Amgen INC. | $121.49 | 2019-2022 | |
| Janssen Biotech, INC. | $98.43 | 2019-2025 | Rybrevant, Carvykti |
| Kite Pharma, INC. | $96.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.32 | 2023-2025 | Ojjaara, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $85.21 | 2024 | Fruzaqla |
| Iovance Biotherapeutics, INC. | $75.24 | 2025 | Amtagvi |
| Sobi, INC | $74.93 | 2024-2025 | |
| Astellas Pharma US INC | $74.90 | 2023-2025 | Xospata, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $65.89 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $64.26 | 2019-2020 | |
| Geron Corporation | $59.05 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $57.48 | 2021-2024 | Zepzelca |
| Shield Therapeutics INC | $51.31 | 2025 | |
| Emd Serono, INC. | $50.11 | 2019-2021 | |
| Octapharma USA, INC. | $47.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.68 | 2020-2025 | |
| Incyte Corporation | $40.54 | 2024-2025 | Monjuvi |
| Servier Pharmaceuticals LLC | $39.68 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $37.51 | 2019 | |
| Lilly USA, LLC | $34.66 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Epizyme, INC. | $30.00 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $29.18 | 2023-2024 | Sancuso |
| Sun Pharmaceutical Industries INC. | $27.92 | 2023 | Yonsa, Odomzo |
| Taiho Oncology, INC. | $27.84 | 2024 | |
| Alexion Pharmaceuticals, INC. | $27.27 | 2019 | |
| Menarini Silicon Biosystems, INC. | $26.56 | 2023 | Cellsearch |
| Verastem, INC. | $25.11 | 2019 | |
| Caris Mpi, INC. | $24.59 | 2025 | Mi Cancer Seek |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Adc Therapeutics America, INC. | $23.54 | 2023 | |
| Legend Biotech USA INC. | $23.17 | 2025 | Carvykti |
| Nuvation Bio INC. | $21.91 | 2025 | Ibtrozi |
| Agios Pharmaceuticals, INC. | $21.69 | 2024 | Pyrukynd |
| Springworks Therapeutics, INC. | $20.68 | 2024 | Ogsiveo |
| Merck Sharp & Dohme LLC | $20.58 | 2025 | Keytruda |
| Fresenius Kabi USA, LLC | $16.69 | 2023 | Stimufend |
| Sumitomo Pharma America, INC. | $15.80 | 2023 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $15.79 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Lamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.